Oncology (all articles)
Somatic Genomic Testing in Patients with Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion.
21 Feb, 2022 | 08:47h | UTC
IPSO Pediatric Surgical Oncology Surgical Practice Guidelines.
21 Feb, 2022 | 08:44h | UTCInternational Society of Paediatric Surgical Oncology (IPSO) Surgical Practice Guidelines – eCancer
Review: Cancer-associated venous thromboembolism.
21 Feb, 2022 | 08:42h | UTCCancer-associated venous thromboembolism – Nature Reviews Disease Primers (if the link is paywalled, try this one)
Infographic: Cancer-associated venous thromboembolism – Nature Reviews Disease Primers (if the link is paywalled, try this one)
Related:
NCCN Guideline: Cancer-Associated Venous Thromboembolic Disease.
ASH 2021 guidelines for prevention and treatment of venous thromboembolism in patients with cancer
Review: venous and arterial thromboembolism in patients with cancer.
RCT: Two vs. three courses of preoperative cisplatin and fluorouracil plus docetaxel for locally advanced esophageal squamous cell carcinoma.
21 Feb, 2022 | 08:25h | UTCMulticenter randomised trial of two versus three courses of preoperative cisplatin and fluorouracil plus docetaxel for locally advanced oesophageal squamous cell carcinoma – British Journal of Cancer (link to abstract – read for free here)
Commentary on Twitter
Multicenter randomised trial of two versus three courses of preoperative cisplatin and fluorouracil plus docetaxel for locally advanced oesophageal squamous cell carcinoma
Read for free: https://t.co/vXRAP29FRo#Chemotherapy #Cancer pic.twitter.com/D7KBifTFOS
— British Journal of Cancer (@BrJCancer) February 9, 2022
Isatuximab plus pomalidomide and low-dose dexamethasone vs. pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study.
21 Feb, 2022 | 08:13h | UTCIsatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study – The Lancet Oncology (link to abstract – $ for full-text)
RCT: Darolutamide and survival in metastatic, hormone-sensitive prostate cancer.
18 Feb, 2022 | 08:47h | UTC
Commentary on Twitter
Adding darolutamide to androgen-deprivation therapy and docetaxel significantly increased overall survival among patients with metastatic, hormone-sensitive prostate cancer. #GU22 https://t.co/GkQZdKgtJs pic.twitter.com/3e5S7tW1Zw
— NEJM (@NEJM) February 17, 2022
German Guidelines for the diagnosis, therapy and follow-up of cervical cancer – Part 1 with recommendations on epidemiology, screening, diagnostics and therapy.
17 Feb, 2022 | 08:47h | UTC
ASCRS Guidelines for the management of colon cancer.
17 Feb, 2022 | 08:49h | UTC
Commentary on Twitter
This #DCRJournal highlights CPG: Colon Cancer – see all in these visual abstracts: https://t.co/qGE9lqZiIc@JonVogel7 @a_bham18 @alexhawkinsmd @seanlangenfeld @ajthorsenL @ColonCancerDoc @AmyLightnerMD @ianmpaquette @KyleCologne @SamAtallahMD @debby_keller @SeanLangenfeld pic.twitter.com/xqLeCF0lGz
— DCRjournal (@DCRjournal) February 7, 2022
Supportive care needs of men with prostate cancer: A systematic review of qualitative studies.
17 Feb, 2022 | 08:34h | UTC
M-A: Immune checkpoint inhibitors combined with chemotherapy compared with chemotherapy alone for triple-negative breast cancer.
17 Feb, 2022 | 08:13h | UTC
Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid review.
16 Feb, 2022 | 10:13h | UTC
Commentary on Twitter
A review of the 23 studies of Covid vaccination for immunocompromised people indicates the level of responders varies with conditions. Even additional doses may not provide sufficient protection for some, requiring additional measureshttps://t.co/BjaKrJUAbO @LancetGH pic.twitter.com/EYVWAX23Ig
— Eric Topol (@EricTopol) February 15, 2022
Consensus Statement: Head and neck cancer survivorship.
16 Feb, 2022 | 08:49h | UTCRelated:
Head and Neck Cancer Survivorship Care Guideline
American Cancer Society Head and Neck Cancer Survivorship Care Guideline
Veno-venous extracorporeal membrane oxygenation (vv-ECMO) for severe respiratory failure in adult cancer patients: a retrospective multicenter analysis.
16 Feb, 2022 | 08:30h | UTC
Commentary on Twitter
VV #ECMO in adults with cancer developing severe respiratory failure: survival remains poor, no significant advantage, carefully select! Low PLT, elevated lactate, disease status: adverse prognostic factors to be considered as deciding to provide #ECLS.
🖇️ https://t.co/igatEJH3VS pic.twitter.com/vl7UQKauB0— Intensive Care Medicine (@yourICM) February 12, 2022
EAACI Position Paper: Hypersensitivity reactions to chemotherapy.
15 Feb, 2022 | 09:54h | UTCHypersensitivity reactions to chemotherapy: an EAACI Position Paper – Allergy
M-A: In patients undergoing colorectal surgery with pelvic dissection, removing urinary catheters on postoperative days 3–4 may provide a balance, minimizing the risk of urine retention (increased when taken too soon) and urinary tract infections (increased when taken too late).
15 Feb, 2022 | 09:45h | UTC
Aromatase inhibitors vs. tamoxifen in premenopausal women with estrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomized trials
13 Feb, 2022 | 21:32h | UTCCommentaries:
Aromatase Inhibitors May Benefit Premenopausal Women With Breast Cancer – HealthDay
RCT: Trametinib improves progression-free survival compared to standard of care in patients with recurrent low-grade serous ovarian cancer.
13 Feb, 2022 | 21:30h | UTC
Commentary on Twitter
Trial findings suggest MEK inhibitor, trametinib, represents new standard-of-care option for patients with recurrent low-grade serous carcinoma. https://t.co/69glZZdrZF pic.twitter.com/UHeccCj1Rn
— The Lancet (@TheLancet) February 10, 2022
Comprehensive imaging characterization of colorectal liver metastases.
13 Feb, 2022 | 21:27h | UTCComprehensive Imaging Characterization of Colorectal Liver Metastases – Frontiers in Oncology
RCT: Survival with Cemiplimab in recurrent cervical cancer.
11 Feb, 2022 | 08:36h | UTCSurvival with Cemiplimab in Recurrent Cervical Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Cemiplimab Prolongs Survival in Recurrent Cervical Cancer – HealthDay
RCT: Event-free survival with pembrolizumab in early triple-negative breast cancer.
11 Feb, 2022 | 08:35h | UTCEvent-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary (before publication): KEYNOTE-522: Neoadjuvant Pembrolizumab Improves Event-Free Survival in Triple-Negative Breast Cancer – The ASCO Post
ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer?
11 Feb, 2022 | 08:23h | UTC
M-A: Clinical outcomes and adverse events after first-line treatment in metastatic renal cell carcinoma.
11 Feb, 2022 | 08:15h | UTC
Review | Molecular imaging in oncology: Current impact and future directions.
11 Feb, 2022 | 08:12h | UTC
Review: Immunotherapies for hepatocellular carcinoma.
11 Feb, 2022 | 08:11h | UTCImmunotherapies for hepatocellular carcinoma – Cancer Medicine
Abemaciclib with endocrine therapy in the treatment of high-risk early breast cancer: ASCO optimal adjuvant chemotherapy and targeted therapy guideline rapid recommendation update.
10 Feb, 2022 | 08:33h | UTC